Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.
Read More…
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
CIKN/A
Phone+49-6172-6080
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Fresenius SE & Co KGaA (FRA:FRE) Frequently Asked Questions
What is Fresenius SE & Co KGaA's stock symbol?
Fresenius SE & Co KGaA trades on the FRA under the ticker symbol "FRE."
What price target have analysts set for FRE?
20 Wall Street analysts have issued 12 month price objectives for Fresenius SE & Co KGaA's stock. Their forecasts range from €43.00 to €78.00. On average, they anticipate Fresenius SE & Co KGaA's share price to reach €57.93 in the next twelve months. This suggests a possible upside of 36.4% from the stock's current price. View Analyst Price Targets for Fresenius SE & Co KGaA.
What is the consensus analysts' recommendation for Fresenius SE & Co KGaA?
20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fresenius SE & Co KGaA in the last year. There are currently 9 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fresenius SE & Co KGaA.
Has Fresenius SE & Co KGaA been receiving favorable news coverage?
Media headlines about FRE stock have been trending very negative recently, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Fresenius SE & Co KGaA earned a news impact score of -3.9 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the company's share price in the near future. View News Stories for Fresenius SE & Co KGaA.
What other stocks do shareholders of Fresenius SE & Co KGaA own?
Who are Fresenius SE & Co KGaA's key executives?
Fresenius SE & Co KGaA's management team includes the folowing people:
- Gerd Krick, Chairman of the Supervisory Board
- Stephan Sturm, Chief Executive Officer (Age 52)
- Niko Stumpfoegger, Deputy Chairman of the Supervisory Board, Employee Representative
- Juergen Goetz, Chief Legal and Compliance Officer, Labor Relations Director, Member of the Management Board
- Francesco De Meo, Member of the Management Board, Chief Executive Officer of Fresenius Helios
- Mats Christer Henriksson, Member of the Management Board, Chief Executive Officer Fresenius Kabi
- Rice Powell, Member of the Management Board, Chief Executive Officer of Fresenius Medical Care (Age 61)
- Ernst Wastler, Member of the Management Board, Chief Executive Officer Fresenius Vamed
- D. Michael Albrecht, Member of the Supervisory Board
- Michael Diekmann, Member of the Supervisory Board (Age 63)
What is Fresenius SE & Co KGaA's stock price today?
One share of FRE stock can currently be purchased for approximately €42.46.
What is Fresenius SE & Co KGaA's official website?
How can I contact Fresenius SE & Co KGaA?
Fresenius SE & Co KGaA's mailing address is Else-Kroener-Str. 1, BAD HOMBURG VOR DER HOEHE, 61352, Germany. The company can be reached via phone at +49-6172-6080.
MarketBeat Community Rating for Fresenius SE & Co KGaA (FRA FRE)
MarketBeat's community ratings are surveys of what our community members think about Fresenius SE & Co KGaA and other stocks. Vote "Outperform" if you believe FRE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FRE will underperform the S&P 500 over the long term. You may vote once every thirty days.
